Full Press Release Details
Lexaria Forward Stock Split
Kelowna, BC November 18, 2015 - Lexaria Corp.
(LXRP-OTCQB) (LXX-CSE) (the "Company" or "Lexaria") announces its Board
of Directors has approved a forward stock split of 1.1 new shares for every
existing common share held.
The forward stock split will take effect as soon as possible
after application to the Financial Industry Regulatory Authority (FINRA) is made
and approval received, and will result in a new CUSIP number being issued when
the forward split is declared effective. All shareholders who own shares in the
Company as of the effective date, which is expected near the middle of December,
will receive 1.1 new shares for every 1.0 share they own as of that date, and
commencing on that date the Company s shares will trade on a post-split basis.
There will be a mandatory conversion period to exchange all
existing share positions, with a deadline to be announced. This action is
expected to lead to higher liquidity and more transparent and efficient trading
for shareholders. The Company is investigating additional actions it can take in
the pursuit of an open and efficient marketplace for its shareholders.
Lexaria has undergone a remarkable corporate pivot that began
in 2014 as it first examined methods of entering the legal cannabis sector and
subsequently refined its focus to concentrate on methods of delivering higher
absorption rates through edible consumption of certain molecules that include
The Company, together with its subsidiary ViPovaTM
Tea has rolled out 11 new consumer products over the past 8 months
including tea, coffee, hot cocoa, and energy bars. The pace of new product
development will now slow as the Company concentrates its efforts on access to
sales and distribution channels.
Lexaria is a food sciences company, with common shares quoted
in the USA with symbol LXRP and in Canada with symbol LXX. The company searches
for projects that could provide potential above-market returns.
To learn more about Lexaria Corp. visit
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: the
completion and effective date of the proposed forward split, achieving sales
through any retail distribution channels such as dispensaries or traditional
retailers. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Access to capital,
or lack thereof, is a major risk and there is no assurance that the Company will
be able to raise required working capital. Factors which could cause actual
results to differ materially from those estimated by the Company include, but
are not limited to, government regulation, managing and maintaining growth, the
effect of adverse publicity, litigation, competition, the patent application and
approval process and other factors which may be identified from time to time in
the Company's public announcements and filings. There is no assurance that the
medical marijuana, hemp oil sector, or alternative health businesses will
provide any benefit to Lexaria, or that the Company will experience any growth
through participation in these sectors. There is no assurance that existing
capital is sufficient for the Company's needs or that it will not need to
attempt to raise additional capital. There is no assurance that any planned
corporate activity, business venture, or initiative will be pursued, or if
pursued, will be successful. There is no assurance that any hemp oil or
cannabinoid-based product will promote, assist, or maintain any beneficial human
health conditions whatsoever. There is no assurance that the cannabinoid/lipid
infusion technology will provide any increase in bioavailability to any
individual person. There is no assurance that any patent application in the USA
or any other nation or under any treaty will result in the award of an actual
patent; nor that an award of any actual patent will protect against challenges
from unknown third parties. There is no assurance that any of Lexaria s
postulated uses, benefits, or advantages for the patent-pending technology will
in fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). ViPovaTM
products and Lexaria Energy products are not intended to diagnose, treat, cure
or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.